caffeine has been researched along with Parkinson Disease, Secondary in 16 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| " After three weeks as a recovery period, 6-OHDA-induced bradykinesia and balance disturbances were assessed by using beam traversal test 10, 30 and 60 minutes after intraperitoneal injections of the drugs (caffeine, SCH58261)." | 3.83 | Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat. ( Mahmoudi, J; Reyhani-Rad, S, 2016) |
| "A dose-response meta-analysis was carried out between Parkinson's disease (PD) risk, and coffee, tea and caffeine consumption." | 2.50 | Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. ( Li, S; Qi, H, 2014) |
| "A reduced risk for Parkinson's disease (PD) among cigarette smokers has been observed consistently during the past 30 years." | 1.31 | Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. ( Checkoway, H; Franklin, GM; Longstreth, WT; Powers, K; Smith-Weller, T; Swanson, PD, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, H | 1 |
| Li, S | 1 |
| Reyhani-Rad, S | 1 |
| Mahmoudi, J | 1 |
| Song, L | 1 |
| Kong, M | 1 |
| Ma, Y | 1 |
| Ba, M | 1 |
| Liu, Z | 1 |
| Kalda, A | 1 |
| Herm, L | 1 |
| Rinken, A | 1 |
| Zharkovsky, A | 1 |
| Chen, JF | 3 |
| Xu, K | 1 |
| Xu, YH | 1 |
| Schwarzschild, MA | 2 |
| Yadav, S | 1 |
| Gupta, SP | 1 |
| Srivastava, G | 1 |
| Srivastava, PK | 1 |
| Singh, MP | 1 |
| Morelli, M | 1 |
| Coccurello, R | 1 |
| Breysse, N | 1 |
| Amalric, M | 1 |
| Joghataie, MT | 1 |
| Roghani, M | 1 |
| Negahdar, F | 1 |
| Hashemi, L | 1 |
| Bové, J | 1 |
| Serrats, J | 1 |
| Mengod, G | 1 |
| Cortés, R | 1 |
| Tolosa, E | 1 |
| Marin, C | 1 |
| Yu, L | 1 |
| Bata-García, JL | 1 |
| Villanueva-Toledo, J | 1 |
| Gutiérrez-Ospina, G | 1 |
| Alvarez-Cervera, FJ | 1 |
| Heredia-López, FJ | 1 |
| Góngora-Alfaro, JL | 1 |
| Sääksjärvi, K | 1 |
| Knekt, P | 1 |
| Rissanen, H | 1 |
| Laaksonen, MA | 1 |
| Reunanen, A | 1 |
| Männistö, S | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Ascherio, A | 1 |
| Zhang, SM | 1 |
| Hernán, MA | 1 |
| Kawachi, I | 1 |
| Colditz, GA | 1 |
| Speizer, FE | 1 |
| Willett, WC | 1 |
| Checkoway, H | 1 |
| Powers, K | 1 |
| Smith-Weller, T | 1 |
| Franklin, GM | 1 |
| Longstreth, WT | 1 |
| Swanson, PD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Parkinson's, Genes and Environment (PAGE) Study[NCT00367900] | 3,100 participants (Actual) | Observational | 2006-08-21 | Completed | |||
| Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)[NCT02008721] | Phase 3 | 92 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for caffeine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease.
Topics: Aged; Caffeine; Coffee; Dose-Response Relationship, Drug; Female; Humans; Male; Parkinson Disease, S | 2014 |
Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervo | 2003 |
14 other studies available for caffeine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Hypokinesia; Male; Mot | 2016 |
Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Dopamine a | 2009 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Str | 2009 |
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Corpus Striatum; Dopamine; Male; Mi | 2010 |
Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse.
Topics: Animals; Caffeine; Inflammation Mediators; Male; Maneb; Mice; Neuroprotective Agents; Nitric Oxide; | 2012 |
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain; Caffeine; Conditioning, Operant; Dopamine; Dopami | 2004 |
Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Caffeine; Cell Count; Central Nervous | 2004 |
Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cell Count; Dynorphins; Enkephalins; Globus Pa | 2005 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, An | 2006 |
Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl.
Topics: Animals; Antiparkinson Agents; Brain; Caffeine; Central Nervous System Stimulants; Dose-Response Rel | 2007 |
Prospective study of coffee consumption and risk of Parkinson's disease.
Topics: Age Factors; Aged; Caffeine; Coffee; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hu | 2008 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antip | 2007 |
Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.
Topics: Adult; Aged; Caffeine; Coffee; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disea | 2001 |
Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake.
Topics: Adult; Aged; Alcohol Drinking; Caffeine; Case-Control Studies; Coffee; Cola; Female; Humans; Male; M | 2002 |